| 1 |
32039550 | DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register. | 2020 Apr |
1 |
| 2 |
28888219 | Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation. | 2018 Jan |
2 |
| 3 |
29526957 | Efficacy of Oral Factor Xa Inhibitor for Venous Thromboembolism in a Patient with Antithrombin Deficiency. | 2018 Jul 15 |
1 |
| 4 |
28794370 | The Successful Prevention of Thromboembolism Using Rivaroxaban in a Patient with Antithrombin Deficiency during the Perioperative Period. | 2017 Sep 1 |
1 |
| 5 |
30279820 | Successful treatment of a massive pulmonary embolism using rivaroxaban in a patient with antithrombin III deficiency. | 2017 Nov |
1 |
| 6 |
25869030 | Successful treatment with rivaroxaban of an extended superficial vein thrombosis in a patient with acquired antithrombin deficiency due to Peg-asparaginase treatment. | 2015 Jul |
1 |
| 7 |
22534775 | Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. | 2012 Jul |
1 |
| 8 |
20946166 | Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. | 2011 Jan |
1 |
| 9 |
21655672 | Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. | 2011 Jul |
1 |
| 10 |
19170587 | Rivaroxaban: a novel, oral, direct factor Xa inhibitor. | 2009 Feb |
1 |